摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(4-甲酰基苯氧基)-3-吡啶甲腈 | 676501-68-1

中文名称
6-(4-甲酰基苯氧基)-3-吡啶甲腈
中文别名
——
英文名称
6-(4-formylphenoxy)-3-pyridinecarbonitrile
英文别名
6-(4-formyl-phenoxy)-nicotino-nitrile;6-(4-Formylphenoxy)nicotinonitrile;6-(4-formylphenoxy)pyridine-3-carbonitrile
6-(4-甲酰基苯氧基)-3-吡啶甲腈化学式
CAS
676501-68-1
化学式
C13H8N2O2
mdl
——
分子量
224.219
InChiKey
PFLGGJSTWOWOQN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    63
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933399090

SDS

SDS:2ce149da0d6c7d39b35bad6e24be2565
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(4-甲酰基苯氧基)-3-吡啶甲腈双氧水 作用下, 以 二甲基亚砜 为溶剂, 反应 2.0h, 以79%的产率得到6-(4-甲酰基苯氧基)吡啶-3-甲酰胺
    参考文献:
    名称:
    Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer
    摘要:
    Arylphenylpyrrolidinylmethylphenoxybenzamides were found to have high affinity and selectivity for K opioid receptors. On the basis of receptor binding assays in Chinese hamster ovary (CHO) cells expressing cloned human opioid receptors, (S)-3-fluoro-4-(4-((2-(3-fluorophenyppyrrolidin-1-yl)methyl)phenoxy)benzamide (25) had a K-i = 0.565 nM for kappa opioid receptor binding while having a K-i = 35.8 nM for mu opioid receptors and a K-i = 211 nM for delta opioid receptor binding. Compound 25 was also a potent antagonist of K opioid receptors when tested in vitro using a [S-35]-guanosine 5'O-[3-thiotriphosphate] ([S-35]GTP-gamma-S) functional assay in CHO cells expressing cloned human opioid receptors. Compounds were also evaluated for potential use as receptor occupancy tracers. Tracer evaluation was done in vivo, using liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods, precluding the need for radiolabeling. (S)-3-Chloro-4-(4-((2-(pyridine-3-yl(pyrrolidin-1-yl)methyl)phenoxy)benzamide (18) was found to have favorable properties for a tracer for receptor occupancy, including good specific versus nonspecific binding and good brain uptake.
    DOI:
    10.1021/jm200789r
  • 作为产物:
    描述:
    6-氯-3-氰基吡啶对羟基苯甲醛potassium carbonate 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 3.0h, 以55%的产率得到6-(4-甲酰基苯氧基)-3-吡啶甲腈
    参考文献:
    名称:
    [EN] OPIOID RECEPTOR ANTAGONISTS
    [FR] ANTAGONISTES DE RECEPTEUR D'OPIOIDES
    摘要:
    公式(I)的化合物;其中变量X1至X10,R1至R7包括R3',E,W,v,y,z,A和B如描述,或者是药用可接受的盐、溶剂化合物、对映体、拉克麦特、二对映体或其混合物,用于治疗、预防或改善肥胖和相关疾病。
    公开号:
    WO2005066164A1
点击查看最新优质反应信息

文献信息

  • [EN] DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST<br/>[FR] DIARYLE ETHERS UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEUR OPIOIDES
    申请人:LILLY CO ELI
    公开号:WO2004026305A1
    公开(公告)日:2004-04-01
    A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    公式(I)的化合物,其中变量X1至X10,R1至R7包括R3',E,v,y,z,A和B如所述,或其药用盐,溶剂化物,对映体,消旋体,非对映异构体或其混合物,用于治疗、预防或改善肥胖和相关疾病。
  • [EN] 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] PYRIDINES 2,6-DISUBSTITUÉES COMME ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2009071504A1
    公开(公告)日:2009-06-11
    Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.
    公开的是式(I)的化合物,其中R1和R2分别选自氢、卤素、CF3、C1-4烷基和烯丙基;Y代表(II)、(III)、(IV)或(V),其中R3代表CF3或C1-4烷基;而R3a代表CF3或C1-4烷基。
  • Diaryl ethers as opioid receptor antagonist
    申请人:Blanco-Pillado Maria-Jesus
    公开号:US20060217372A1
    公开(公告)日:2006-09-28
    A compound of the formula (I) wherein the variables X 1 to X 10 , R 1 to R 7 including R 3′ , E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    本发明公开了一种化合物(I)的公式,其中变量X1至X10,R1至R7包括R3',E,v,y,z,A和B如所述,或其药学上可接受的盐,溶剂合物,对映体,外消旋体,非对映体异构体或其混合物,用于治疗、预防或缓解肥胖和相关疾病。
  • NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
    申请人:BISCHOFF Alexander
    公开号:US20090221583A1
    公开(公告)日:2009-09-03
    The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    本发明涉及作为硬脂酰辅酶A去饱和酶抑制剂的吡啶二元衍生物。本发明还涉及制备该化合物的方法、含有该化合物的组合物以及使用该化合物进行治疗的方法。
  • Opioid receptor antagonists
    申请人:De La Torre Garcia Marta
    公开号:US20070112036A1
    公开(公告)日:2007-05-17
    A compound of the formula (I); wherein the variables X 1 to X 10 , R 1 to R 7 including R 3′ , E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    本发明涉及化合物(I)的制备,其中变量X1到X10,R1到R7包括R3',E,W,v,y,z,A和B如所述,或其药学上可接受的盐,溶剂合物,对映体,外消旋体,非对映体异构体或其混合物,用于治疗、预防或缓解肥胖症及相关疾病。
查看更多